Table 1 Comparison of Groups Based on Delayed Graft Function (DGF) Days
No DGF | DGF days | P value | |||
|---|---|---|---|---|---|
0 (n = 696) | < 14 (n = 749) | 15–28 (n = 217) | > 28 (n = 52) | ||
Donor age (years) | 36.9 (19.1) | 40(15.6) | 41.5(14.8) | 46(12) | < 0.001 |
Male | 425 (61%) | 463(62%) | 146(66.4%) | 19 (47.5%) | 0.135 |
Donor Body mass index (kg/m2) | 26.7 (7.4) | 29.9(7.8) | 29.6(7.6) | 30(10.5) | < 0.001 |
Donor Hypertension | 161(24.2%) | 209 (29%) | 62 (29%) | 22 (46%) | 0.005 |
Donor Black race | 46 (6.6%) | 62(8%) | 15(7%) | 2(4%) | 0.47 |
Donor Acute Kidney Injury stage ≥ 2 | 94 (13.5%) | 385(51%) | 130(60%) | 20(39%) | < 0.001 |
KDPI | 46.6 (28.9) | 52.7(24.7) | 54.8(25.1) | 62 [21] | < 0.001 |
KDPI ≥ 85 | 104 (15%) | 92(12%) | 32(15%) | 9(17%) | 0.5 |
Donation after circulatory death | 106(15.2%) | 196(26%) | 59(27%) | 20(39%) | < 0.001 |
Donor on inotropes | 213(30.6%) | 243(32%) | 78(36%) | 15(38%) | 0.43 |
Donor Diabetes mellitus | 69(10.1%) | 57(7.8%) | 16(7.4%) | 6(12%) | 0.31 |
Donor terminal creatinine (mg/dl) | 1.27(1.39) | 3.1(2.8) | 3.6(2.9) | 2.5(2.3) | < 0.001 |
Cold Ischemia time > 24 h | 125(18%) | 247(33%) | 68(31%) | 22(42%) | < 0.001 |
Cold Ischemia time (hours) | 16.9 (7.3) | 20.8(6.7) | 21.4(6.2) | 21.7[8] | < 0.001 |
Pumped kidney | 60(9%) | 92(12%) | 21(10%) | 8 (15%) | 0.4 |
Warm ischemia time (minutes) | 28.11[12] | 24.8[10] | 29 [11] | 21 (6.8) | 0.32 |
Recipient Male | 351(50.4%) | 482(64%) | 145(66%) | 32(76%) | < 0.001 |
Recipient Black race | 68(9.8%) | 93(12.4%) | 31(14.3%) | 5(9.6%) | 0.21 |
Recipient Age at transplant (years) | 54.4(14.0) | 56.1[13] | 56.5[12] | 56.8[12] | 0.04 |
Recipient Body mass index (kg/m2) | 28.1(5.6) | 29.1(5.6) | 29.9(5.8) | 31.2(5.5) | < 0.001 |
Recipient Length on Dialysis (days) | 1306.2(1042) | 1365.3(942) | 1504(895) | 1540 (850) | 0.04 |
Pretransplant Diabetes mellitus | 250(35.9%) | 347(46%) | 120(55%) | 28(54%) | < 0.001 |
Previous transplant | 87(12.5%) | 69(9.2%) | 21(9.5%) | 5(9.6%) | 0.21 |
Panel reactive antibody (%) | 21.91(35.5) | 17.8(32.4) | 18.7(31.6) | 16.5(29.5) | 0.11 |
Induction Basiliximab Rabbit‐anti thymocyte globulin Alemtuzumab | Basiliximab-165(25%) Rabbit‐anti thymocyte globulin -139(21%) Alemtuzumab-355(54%) | Basiliximab-203 (29%) Rabbit‐anti thymocyte globulin -87 (12%) Alemtuzumab-418(59%) | Basiliximab-60(29%) Rabbit‐anti thymocyte globulin -26(13%) Alemtuzumab-120(59%) | Basiliximab-15(33%) Rabbit‐anti thymocyte globulin -6(13%) Alemtuzumab-26 (54%) | < 0.001 |
Continuous variables given as mean (standard deviation); categorical variables given as frequency (percentage) | |||||